New award for lamotrigine tablets with jubilant cadista. Ordering period is june 16, 2025 to june 15, 2026 with four one-year options.
Active Indefinite Delivery Contract Awarded Last action
- Contract number
- 36E79725D0029
- Awardee
-
Jubilant Cadista Pharmaceuticals Inc. UEI KMQQLKRF5ZE5
- Awarding agency
-
National Acquisition Center
Headquarters, Department of Veterans Affairs
- Task orders
- 0
Award facts
- Opportunity
-
- 6505--Lamotrigine Immediate Release (IR) Tablets Pre-Solicitation · 36E79725R0004 · Posted Oct 23, 2024
- Last date to order 69% complete
- IDV ceiling
- $11,913,264.25
- Award type
- Single award
- Contracting staff
- NAICS code
- 325412 Pharmaceutical Preparation Manufacturing
- PSC
- 6505 Drugs And Biologicals
- Set-aside
- No set-aside
- Competition
- Full and Open Competition · 6 offers Negotiated Proposal / Quote
- Pricing
- Firm Fixed Price
Award details come from SAM.gov/FPDS.
About this IDV
The Department of Veterans Affairs National Acquisition Center awarded a single-award indefinite-delivery contract to Jubilant Cadista Pharmaceuticals Inc. for Lamotrigine Immediate Release tablets with a ceiling of $11,913,264.25 on June 16, 2025.
The contract carries no set-aside designation. Place of performance includes distribution through the VA's and DoD's Pharmaceutical Prime Vendor Programs to serve the Department of Veterans Affairs, Department of Defense, Bureau of Prisons, Indian Health Service, and Federal Health Care Center.
The originating solicitation, posted October 23, 2024, sought an unrestricted procurement of Lamotrigine IR tablets in multiple strengths and bottle configurations. Estimated annual usage ranged from 10,704 bottles of 500-count 150mg tablets to 45,951 bottles of 60-count 200mg tablets. Offerors were required to provide a unique National Drug Code number and label, with packaging meeting specified safety cap and bottle dimension requirements. Clinicians retain the ability to prescribe the branded product Lamictal; when a generic is deemed clinically appropriate, the awarded contract product serves as the mandatory source.
The ordering period runs June 16, 2025 through June 15, 2026, with four one-year option periods extending the ultimate completion date to June 15, 2027. A modification implemented Executive Order 14398 discrimination language into the national contract master schedule.
Transactions
| Action | Obligated | Date |
|---|---|---|
| Supplemental Agreement for work within scope | $0 | |
| Other Administrative Action | $0 | |
| Exercise an Option | $0 | |
| Add Subcontract Plan | $0 | |
| Add Subcontract Plan | $0 | |
| Original award | $0 |
Quick answers
Who was awarded contract 36E79725D0029?
36E79725D0029 was awarded to Jubilant Cadista Pharmaceuticals Inc. by National Acquisition Center (Headquarters) on June 16, 2025.
How much is contract 36E79725D0029 worth?
36E79725D0029's own ceiling is $11,913,264.
Who can order from contract 36E79725D0029?
36E79725D0029 is a single award indefinite delivery contract.
Was contract 36E79725D0029 competed?
The extent of competition for 36E79725D0029 was full and open competition. The government received 6 offers.
On GovTribe
See this IDV's full record
- Every order and transaction
- The awardee's other awards and teaming partners
- Similar IDVs and recompete opportunities
- Ask GovTribe AI about this IDV